At a Glance

If you have ever wondered whether you can actually slow ageing in pets, here is the honest answer: yes, partly — and the single most powerful lever is already in your hands. Decades of evidence point to one intervention that reliably adds healthy years to a dog’s life, and it is not a drug. It is keeping your pet at a lean, healthy body condition.

This guide starts there, then works outward to the frontier. We cover how you feed (meal timing and fasting), the cellular machinery underneath it all (autophagy, the body’s cellular recycling system), and the emerging anti-ageing pill for dogs and rapamycin for dogs that pet parents are increasingly asking about. We look at the first medication ever approved for an ageing-related heart condition in cats, and at what the Dog Aging Project is testing right now.

Whether you share your home with a senior dog, a senior cat, or both, the science of longer life (geroscience) has moved from the laboratory into your vet’s consulting room. Here is what the evidence says, what is still unproven, and what is safe to act on today. Throughout, your vet is your partner: the goal is a better-informed conversation, not a do-it-yourself protocol.

The Full Guide

Start Here: The One Lever With the Strongest Proof

Pet parents often search for: “can we slow ageing in pets,” “how to help my dog live longer,” or “do lean dogs live longer.” Here is what the evidence says, and it is unusually clear.

Most longevity headlines are about drugs. The most robust finding in companion-animal ageing is not. It is about body condition — how lean or heavy your pet is across their whole life.

The landmark evidence is a 14-year study of 48 Labradors, published in 2002 in the Journal of the American Veterinary Medical Association (JAVMA). Littermates were paired and fed the same food; one of each pair simply ate 25 per cent less. The lean-fed dogs lived a median of 13.0 years versus 11.2 years for their heavier siblings — an extra 1.8 years, roughly 15 per cent more life. Just as striking, the lean dogs needed treatment for arthritis around three years later than their heavier littermates.

A 2008 follow-up in the British Journal of Nutrition traced why. Body fat above about 25 per cent was linked to rising insulin resistance, and that metabolic shift independently predicted a shorter life and earlier chronic disease. In other words, lifelong leanness was not just about weight — it changed the body’s ageing biology. We will see exactly how later in this guide.

This is not a single-study fluke. A 2019 analysis in the Journal of Veterinary Internal Medicine looked at more than 50,000 dogs across 12 breeds and found that carrying excess weight shortened lifespan in every single breed, by a few months in some, by more than two years in others. A 2023 dataset in Frontiers in Veterinary Science put numbers on it: dogs at an ideal body condition outlived their obese counterparts by well over a year. Cats, as we will see, are a more complicated story — but for dogs the direction of the evidence is not in doubt.

For Dogs: Lean Is the Goal

For most dogs, the target is a body condition score (BCS) around 4 to 5 on the 9-point scale: you can feel the ribs easily without pressing, and there is a visible waist from above. This is the most evidence-backed, freely available longevity intervention that exists, and it works for every dog, from a pedigree Labrador to an Indie (desi dog) of mixed ancestry. No prescription, no cost, no risk. For cats, as the next section explains, the right number is a more careful judgement.

For Cats: It Is Genuinely More Complicated

Pet parents often ask: “do fatter cats live longer?” It is a fair question, and the data are surprising enough that we need to handle them carefully.

In dogs the message is simple: leaner lives longer. In cats it is not. A large 2018 study in the Journal of Feline Medicine and Surgery, which followed thousands of cats over their lives, found something unexpected. Cats scored at BCS 6 to 8 (conventionally called “overweight”) actually had the longest survival, while very lean cats, below BCS 5, had the highest mortality.

Read carefully, this almost certainly does not mean that letting a cat gain weight extends its life. The far more likely explanation is reverse causation: in cats, becoming thin is often the first visible sign of illness, such as chronic kidney disease, hyperthyroidism, cancer, or dental pain, rather than a cause of early death. The same study’s authors were explicit that living longer is not the same as living well, and that obese cats still carried real disease risk. Severe obesity (BCS 9) was linked to the shortest lifespan of all.

So the honest takeaway for cats is not “lean is always better” and certainly not “heavier is better.” It is that feline body condition is its own science, and sudden weight loss in a cat is a reason to see your vet, not to celebrate. Your vet is the only one who should set your individual cat’s target.

The Counterweight: Lean Is Not the Same as Thin

There is a crucial caveat for older pets of both species. Ageing brings sarcopenia — the gradual loss of lean muscle mass. Apparently healthy cats can lose roughly a third of their lean body mass between ages 10 and 15, and senior dogs lose muscle while often gaining fat, which can hide the loss. This matters because “lean” means lean and well-muscled, never starved.

Senior pets generally need more high-quality protein, not less, to defend their muscle — the opposite of crude calorie-cutting. The right tool is your vet’s body condition score paired with a muscle condition score, judged together. Weight on a scale alone misses muscle loss entirely.

How You Feed, Not Just What: Meal Timing and Fasting

Pet parents often search for: “intermittent fasting for dogs,” “how often should I feed my senior dog,” or “is fasting safe for cats.” The answers differ sharply by species, and one of them is a hard safety line.

Beyond how much your pet eats, when they eat may matter too. In people and laboratory animals, going without food for a stretch flips a “metabolic switch”: once the liver’s sugar stores run low (typically beyond about 12 hours), the body shifts to burning fat and producing ketones, and several repair pathways switch on. A 2019 review in the New England Journal of Medicine describes this fed-to-fasted switch as the heart of why intermittent fasting (IF) and time-restricted feeding (TRF) show metabolic benefits.

But here is where species matters more than almost anywhere else in this guide. What may be a gentle lever in dogs is a genuine danger in cats.

For Cats: A Hard Safety Line

This is not a cautious overstatement. Feline hepatic lipidosis is one of the most common and serious liver conditions in cats, and it is most dangerous in overweight, middle-aged cats who suddenly eat less. If your cat is not eating, the goal is to get food into them and get to your vet — the precise opposite of fasting. For cats, the longevity conversation is about steady, complete nutrition and ideal body condition, not meal timing.

For Dogs: A Gentler, Still-Emerging Lever

Pet parents often ask: “should I feed my dog once or twice a day?” Here is what the largest dataset so far suggests, with appropriate caution.

Dogs are metabolically more flexible. A 2022 analysis from the Dog Aging Project, drawing on more than 24,000 dogs, found that dogs fed once daily had lower odds of several age-related conditions, including cognitive, digestive, dental, kidney, and liver disorders, than dogs fed more often. A small feeding study has shown dogs can shift toward fat-burning during a fast, much as people do.

This is promising, but it is association, not proof. The Dog Aging Project data cannot yet tell us whether once-daily feeding makes dogs healthier or whether healthier dogs simply happen to be fed that way. It is a reasonable, low-risk pattern to discuss with your vet for a healthy adult dog — but it is not a rule, and it is not for every dog.

If you are wondering why meal timing would touch ageing at all, the answer lives one level down — in the same cellular switches that fasting, leanness, and the longevity drugs all pull. That is where we go next.

The Science Underneath: mTOR, AMPK, and “Cellular Recycling”

Pet parents searching for “what is autophagy” or “autophagy supplements for dogs” are circling the cellular idea that ties this whole guide together. Here is the simplest accurate version.

Inside every cell sits a master nutrient sensor called mTOR — short for the mechanistic target of rapamycin. Think of it as a fuel gauge that reads whether the cell is in a fed, build-and-grow state or a fasted, repair-and-recycle state. When food and growth signals are abundant, the main branch of this sensor, mTOR Complex 1 (mTORC1), tells the cell to grow and build, and it switches off the cell’s cleanup crew.

That cleanup crew is autophagy — literally “self-eating,” and better understood as cellular recycling. It is how a cell dismantles worn-out parts, clears damaged proteins, and recycles the pieces. As pets age, this recycling slows down, and the 2023 update to the influential hallmarks of ageing framework, published in the journal Cell, lists “disabled macroautophagy” as one of the core mechanisms of getting old. Sluggish recycling means cellular junk accumulates.

Here is the unifying idea. A second sensor, AMPK (AMP-activated protein kinase), acts as the low-fuel light: when energy runs low (during fasting, exercise, or caloric restriction), AMPK switches on, mTORC1 switches off, and autophagy ramps up.

Keeping a pet lean and occasionally fasted (dogs only) nudges these same switches toward repair. The insulin and insulin-like growth factor 1 (IGF-1) signals that rise with overfeeding push them the other way, toward growth and storage.

This is why everything in this guide connects. Lean body condition, fasting, and the drugs we are about to meet all converge on one place: less mTORC1 signalling, more autophagy, better metabolic flexibility. They are different routes to the same cellular destination.

Rapamycin: The Drug That Mimics Lean Living

Pet parents increasingly search for “rapamycin for dogs” after reading about the Dog Aging Project. Here is what it is, what is genuinely known, and what is still being tested.

Rapamycin has an origin story worthy of its reputation. It was discovered in a soil bacterium collected on Rapa Nui (Easter Island) in the 1960s, which is how it got its name. It is now a well-established prescription medicine in human transplant care, and it is the most rigorously studied anti-ageing candidate in companion animals. It works by directly inhibiting mTORC1 (the master nutrient sensor from the previous section), which switches on autophagy. In effect, it pharmacologically mimics some of what lifelong leanness does.

The flagship study is TRIAD (the Test of Rapamycin in Aging Dogs), run by the Dog Aging Project, a research effort following more than 50,000 companion dogs. TRIAD is a double-masked, placebo-controlled trial that aims to enrol 580 healthy middle-aged dogs, giving a low dose of rapamycin once weekly for a year and then following the dogs for two more.

Its main question is whether treated dogs simply live longer. The trial’s own design paper, published in GeroScience in 2025, calls it the first rigorous test of an anti-ageing drug with lifespan as the endpoint performed outside the laboratory in any species.

That ambition comes with an honest caveat: TRIAD has not reported results. Enrolment is still under way, and a lifespan answer is years off. Anyone claiming rapamycin is proven to extend dogs’ lives is ahead of the evidence.

The earlier groundwork is encouraging but mixed. A 2017 trial in GeroScience gave low-dose rapamycin to 24 middle-aged dogs for ten weeks; it was well tolerated and hinted at improved heart function. A slightly larger follow-up over six months did not reproduce that heart benefit — a reminder that early signals do not always hold up.

What has held up reasonably well is safety: at the low, intermittent doses studied, side effects in dogs have been uncommon, with occasional mild digestive upset and, rarely, raised blood fats.

The reason low weekly dosing looks safer than the daily transplant dose comes back to those two cellular switches. Brief, intermittent dosing appears to dial down mTORC1 without much affecting a related complex, mTORC2, whose suppression is thought to drive most of rapamycin’s metabolic downsides. It is a real drug with real trade-offs — which is exactly why it belongs in your vet’s hands, not a supplement cabinet.

The Regulatory Turning Point: From Theory to the Pharmacy

Pet parents searching for “anti-ageing pill for dogs” or “new drug for cat heart disease” are picking up on something real: regulators have, for the first time, started saying yes.

For decades, slowing ageing in pets was a laboratory idea. In the last two years it has crossed into the regulated world — once for cats, and, step by step, for dogs.

For Cats: The First Drug for Early Heart Disease

Hypertrophic cardiomyopathy (HCM), a thickening of the heart muscle, is the most common heart disease in cats, affecting roughly one in seven, and far more among older cats and among breeds known to carry the risk, such as Maine Coons, Ragdolls, and Persians. Until recently there was no medication approved for the silent, early stage of the disease; vets could monitor but not modify its course.

That changed in March 2025, when the United States Food and Drug Administration (US FDA), through its Center for Veterinary Medicine (CVM), conditionally approved Felycin-CA1 (a once-weekly, delayed-release form of rapamycin) for cats with subclinical HCM. It is the first drug ever approved for feline HCM in any form. The supporting trial, called RAPACAT and published in JAVMA in 2023, followed 43 cats over six months and found that a low weekly dose slowed the thickening of the heart muscle, with side effects no different from placebo.

It is the same molecule we have been discussing, doing in a feline heart what the mechanism predicts: easing the pathological growth that mTORC1 drives. For cat parents, this is the most concrete, vet-prescribable piece of geroscience in this entire guide — a real reason to ask a veterinary cardiologist about early screening, particularly if your cat is one of the at-risk breeds.

For Dogs: The First Pill Aimed Squarely at Lifespan

On the canine side, the company Loyal is developing medicines explicitly intended to extend healthy lifespan. Its injectable candidate, LOY-001, targets IGF-1 (the growth signal that helps explain why large breeds tend to age faster) in big, older dogs. Its daily pill, LOY-002, is designed as a caloric-restriction mimetic for senior dogs, aiming to deliver some of the benefits of lean living without the weight loss.

What makes this a turning point is regulatory, not just scientific. The US FDA has now accepted Loyal’s evidence on two of the three technical questions it must answer for LOY-002: a “reasonable expectation of effectiveness” and, more recently, target-animal safety, leaving manufacturing as the remaining step. The pivotal lifespan trial, called STAY, completed enrolment of around 1,300 dogs in 2025.

It is important to read this precisely, because excitement runs ahead of fact here. Clearing those review stages is not the same as approval, and approval is not the same as a proven extra year of life — the survival data from STAY are still being gathered. If LOY-002 is conditionally approved, it would be the first drug anywhere aimed specifically at extending lifespan in any species. That is genuinely historic, and still genuinely unproven. Both things are true at once.

Senolytics: Clearing the “Zombie Cells”

Pet parents who have read about “zombie cells” or a “senolytic trial in dogs” are asking about a different strategy — not tuning the cell’s recycling, but removing worn-out cells entirely. Here is the careful version.

As bodies age, some cells stop dividing but refuse to die. These senescent cells (our Hallmarks guide called them “zombie cells”) linger and leak inflammatory signals that age the tissue around them. Senolytics are compounds designed to clear them out. The idea is well supported in laboratory animals, where removing these cells improves healthspan.

In human research, the original senolytic combination pairs a chemotherapy drug, dasatinib, with quercetin, a plant flavonoid found in foods like apples and onions. This pairing is often written as dasatinib plus quercetin (D+Q). It is essential to be clear about what this is.

So what is actually known in pets? One controlled trial, published in Scientific Reports in 2024, tested a proprietary senolytic formulation combined with an NAD+ precursor in 70 senior dogs with mild cognitive decline. It reported a modest improvement in pet-parent-reported cognition at three months. Two honest caveats matter: the improvement was not sustained at six months, and the formulation tested was a proprietary blend — importantly, not the prescription D+Q combination from the human work. It is an encouraging early signal, not a finished answer, and not a licence to experiment.

Acarbose and the Other Caloric-Restriction Mimetics

Pet parents who have gone deep on longevity forums sometimes ask about “acarbose for dogs.” It is a real candidate — with a real evidence gap worth understanding.

Acarbose is an old, inexpensive diabetes medicine that slows the digestion of carbohydrates, blunting the spike in blood sugar after a meal. Because that softens the insulin response, it behaves a little like eating less — a caloric-restriction mimetic. In a rigorous United States National Institute on Aging testing programme, acarbose extended the lifespan of mice, notably so in males.

The catch is the species gap. Those results are in mice. There is no published trial showing acarbose extends lifespan or healthspan in dogs or cats. In veterinary medicine it is used only occasionally, as an add-on for some diabetic dogs when insulin alone is not enough. As a longevity tool for pets, it remains an interesting hypothesis, not an established practice.

What You Can Do Today

Whether you have a senior dog, a senior cat, or both, here is how to turn all of this into action — starting with what is proven and free, and ending with what is still on the horizon.

The most reassuring message in this guide is that the strongest intervention needs no prescription and no shopping list. In order of how solid the evidence is:

1. Get a body and muscle condition score at your next vet visit. Ask your vet to assess both (not just weight on a scale) and to set your individual pet’s target. This is the highest-evidence step, and it is free.
2. Feed to that target for life. For dogs, lean and well-muscled is the goal. For cats, work with your vet, because feline body condition is more complex and sudden thinness signals illness.
3. For healthy adult dogs only, discuss meal timing. Once-daily or time-restricted feeding is a reasonable, low-risk pattern to raise with your vet. Never fast a cat.
4. Treat the drugs as a vet-led conversation, not a purchase. Rapamycin, the Loyal medicines, senolytics, and acarbose are prescription-only or still in trials. For cats with suspected heart disease, ask about early HCM screening — because there is now, for the first time, something a vet can do at the early stage.

A note on availability, because it is changing fast. Generic rapamycin has long existed as a human medicine, so a vet who judges it appropriate may be able to discuss it. The cat heart medication and the canine longevity pills described here have so far been cleared only by the US FDA and are not yet widely registered elsewhere — meaning your vet may not be able to prescribe them locally today.

That will evolve. What will not change is the foundation: a lean, well-muscled, well-fed pet, seen regularly by a vet who knows them, is the most powerful longevity plan available — and it always will be.

Sources Cited in This Article

1. Kealy RD, Lawler DF, Ballam JM, et al. (2002). “Effects of diet restriction on life span and age-related changes in dogs.” Journal of the American Veterinary Medical Association, 220(9), 1315–1320.
2. Lawler DF, Larson BT, Ballam JM, et al. (2008). “Diet restriction and ageing in the dog: major observations over two decades.” British Journal of Nutrition, 99(4), 793–805.
3. Salt C, Morris PJ, Wilson D, et al. (2019). “Association between life span and body condition in neutered client-owned dogs.” Journal of Veterinary Internal Medicine, 33(1), 89–99.
4. Teng KT, McGreevy PD, Toribio JALML, et al. (2018). “Strong associations of nine-point body condition scoring with survival and lifespan in cats.” Journal of Feline Medicine and Surgery, 20(12), 1110–1118.
5. Montoya M, Morrison JA, Arrignon F, et al. (2023). “Life expectancy tables for dogs and cats derived from clinical data.” Frontiers in Veterinary Science, 10, 1082102.
6. Bray EE, Zheng Z, Tolbert MK, et al.; Dog Aging Project Consortium (2022). “Once-daily feeding is associated with better health in companion dogs: results from the Dog Aging Project.” GeroScience, 44(4), 1779–1790.
7. de Cabo R, Mattson MP (2019). “Effects of Intermittent Fasting on Health, Aging, and Disease.” New England Journal of Medicine, 381(26), 2541–2551.
8. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G (2023). “Hallmarks of aging: an expanding universe.” Cell, 186(2), 243–278.
9. Coleman AE, Creevy KE, et al.; Dog Aging Project Consortium (2025). “Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs.” GeroScience, 47(3), 2851–2877.
10. Urfer SR, Kaeberlein TL, Mailheau S, et al. (2017). “A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs.” GeroScience, 39, 117–127.
11. Kaplan JL, Rivas VN, Walker AL, et al. (2023). “Delayed-release rapamycin halts progression of left ventricular hypertrophy in subclinical feline hypertrophic cardiomyopathy: results of the RAPACAT trial.” Journal of the American Veterinary Medical Association, 261(11), 1628–1637.
12. United States Food and Drug Administration, Center for Veterinary Medicine (2025). “FDA Conditionally Approves Drug for Management of Ventricular Hypertrophy in Cats” (Felycin-CA1, sirolimus delayed-release tablets, application 141-604).
13. Simon BT, Scott-Moncrieff JC, et al. (2024). “A randomized, controlled clinical trial demonstrates improved owner-assessed cognitive function in senior dogs receiving a senolytic and NAD+ precursor combination.” Scientific Reports, 14, 12399.
14. Harrison DE, Strong R, Allison DB, et al. (2014). “Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.” Aging Cell, 13(2), 273–282.
15. Harrison DE, Strong R, Reifsnyder P, et al. (2019). “Acarbose improves health and lifespan in aging HET3 mice.” Aging Cell, 18(2), e12898.
16. Nelson RW, Robertson J, Feldman EC, Briggs C (2000). “Effect of the alpha-glucosidase inhibitor acarbose on control of glycaemia in dogs with naturally acquired diabetes mellitus.” Journal of the American Veterinary Medical Association, 216(8), 1265–1269.
17. Zhu Y, Tchkonia T, Pirtskhalava T, et al. (2015). “The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs.” Aging Cell, 14(4), 644–658.
18. Pietrocola F, Lachkar V, Enot DP, et al. (2015). “Spermidine induces autophagy by inhibiting the acetyltransferase EP300.” Cell Death & Differentiation, 22(3), 509–516.